Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)

被引：0
|
作者：
Thieblemont, Catherine
Wang, Kaijun
Keeping, Sam
Zhang, Ina
Yang, Keri
Tang, Boxiong
Mohseninejad, Leyla
机构：
[1] Hop St Louis, Paris, France
[2] BeiGene USA Inc, San Mateo, CA USA
[3] BeiGene Switzerland GmbH, Basel, Switzerland
[4] PRECISIONheor, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19527
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [31] A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Potluri, R.
    Chen, C.
    Ranjan, S.
    Kumar, A.
    Bhandari, H.
    Davis, C.
    VALUE IN HEALTH, 2019, 22 : S524 - S524
  • [32] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
    Abramson, Jeremy S.
    Kamdar, Manali
    Liu, Fei Fei
    Crotta, Alessandro
    Previtali, Alessandro
    Klijn, Sven L.
    Wang, Pearl
    Situ, Aaron
    Zhang, Yixie
    Bonner, Ashley
    Lunning, Matthew A.
    BLOOD, 2022, 140 : 4655 - 4656
  • [33] A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF UPADACITINIB VERSUS TOFACITINIB IN CSDMARD-IR PATIENTS WITH MODERATE TO SEVERE RA
    Edwards, Christopher
    Sawant, Ruta
    Du, Ella X.
    Cammarota, Jordan
    Tang, Patrick
    Garg, Vishvas
    Friedman, Alan
    Betts, Keith
    RHEUMATOLOGY, 2020, 59 : 104 - 104
  • [34] MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF TECLISTAMAB VERSUS SELINEXOR-DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/ REFRACTORY MULTIPLE MYELOMA (RRMM)
    Moreau, P.
    Usmani, S. Z.
    van de Donk, N. W. C. J.
    Garfall, A. L.
    Delforge, M.
    Oriol, A.
    Nooka, A.
    Rosinol, L.
    Bahlis, N.
    Otero, Rodriguez P.
    Martin, T.
    Diels, J.
    Van Sanden, S.
    Pei, L.
    Ammann, E.
    Chastain, K.
    Marshall, A.
    Slavcev, M.
    Londhe, A.
    Krishnan, A.
    VALUE IN HEALTH, 2023, 26 (12) : S31 - S31
  • [35] Anchored matching-adjusted indirect comparison (MAIC) of regorafenib (REG) versus cabozantinib (CAB) in advanced hepatocellular carcinoma (HCC).
    Proskorovsky, Irina
    Krotneva, Mira
    Ozgurdal, Kirhan
    Jaeger, Savina
    Su, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Zheng, Yan
    Snider, Julia T.
    Locke, Frederick L.
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3052 - 3062
  • [37] A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
    Allan, John N.
    Kittai, Adam S.
    James, Dan
    Ridge, Helen
    Miranda, Miguel
    Yong, Alan
    Fam, Fady
    Roos, Jack
    Shetty, Vikram
    Davids, Matthew S.
    Skarbnik, Alan
    BLOOD, 2023, 142
  • [38] Matching-adjusted indirect comparisons (MAIC) of safety between single-agent belantamab mafodotin versus selinexor plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)
    Suvannasankha, A.
    Prawitz, T.
    Kapetanakis, V.
    Sarri, G.
    Hughes, R.
    Wang, F.
    Hogea, C.
    Ferrante, S. Allen
    Gutierrez, B.
    Gorsh, B.
    Willson, J.
    Popat, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S654 - S654
  • [39] Similar Efficacy of Ibrutinib Arms across ALPINE and ELEVATE-RR Trials in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Shadman, Mazyar
    Tedeschi, Alessandra
    Mohseninejad, Leyla
    Yang, Keri
    Lamanna, Nicole
    Xu, Sheng
    Cohen, Aileen Cleary
    Challagulla, Swetha
    Xue, Mei
    Williams, Rhys
    O'Brien, Susan M.
    Brown, Jennifer R.
    Tam, Constantine S.
    BLOOD, 2023, 142
  • [40] Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
    Shadman, Mazyar
    Tedeschi, Alessandra
    Mohseninejad, Leyla
    Yang, Keri
    Lamanna, Nicole
    Xu, Sheng
    Cohen, Aileen
    Challagulla, Swetha
    Xue, Mei
    Williams, Rhys
    O'Brien, Susan M.
    Brown, Jennifer R.
    Tam, Constantine
    BLOOD CANCER JOURNAL, 2024, 14 (01):
12345